Sanofi Goes Big On Asia Vaccines With Singapore Investment
Flexibility, Demand, Preparedness Cited
Executive Summary
French giant makes its biggest single investment to date in Asia as it prepares to build up regional vaccine production capacity, in part to help prepare for future pandemics.
You may also be interested in...
New Asia Expansion For BioNTech As It Builds On Global Success
German mRNA specialist choses Singapore as its first regional hub in Asia Pacific, where it also plans to build a manufacturing site to support the global supply of both vaccines and therapeutics and a regional “rapid response” capability for future pandemics.
Sanofi Q1 Preview: Building The Pipeline, Improving Business Efficiencies
Strong sales of Dupixent and its range of vaccines are expected to drive Sanofi’s financial results for the first quarter of 2021, although these are likely to have been adversely affected by currency exchange rate movements. Numerous data readouts are expected in the coming months from pipeline products.
Coronavirus Update: How Vaccines Stack Up Against Variants So Far
Plus: Sanofi is getting into the mRNA vaccine game under a partnership with Translate Bio but has a lot of catching up to do.